Cilia and flagella associated protein 65 (CFAP65): A Potential Drug Target and Biomarker

Target Name: CFAP65

NCBI ID: G255101

CFAP65

Cilia and flagella associated protein 65 (CFAP65): A Potential Drug Target and Biomarker

Cilia and flagella associated protein 65 (CFAP65) is a protein that plays a crucial role in the function of cilia and flagella, which are structures found in many organisms, including humans. Cilia and flagella are essential for the movement of cells, and their dysfunction has been linked to various diseases, including cancer, neurodegenerative diseases, and respiratory infections. Therefore, identifying potential drug targets and biomarkers for CFAP65 could have a significant impact on our understanding of these diseases and their treatments.

Disease-Related Characteristics of CFAP65

CFAP65 is a member of the superfamily of cytoskeletal proteins, which are involved in the structure and function of cells. It is a 21-kDa protein that consists of 195 amino acid residues. CFAP65 is expressed in many tissues and cells in the human body, including the epithelial, muscle, heart, and nervous systems. It is also expressed in various diseases, including cancer, neurodegenerative diseases, and respiratory infections.

One of the most significant features of CFAP65 is its role in the function of cilia and flagella. These structures are essential for the movement of cells and are involved in various physiological processes, including cell signaling and transport. The dysfunction of cilia and flagella has been linked to various diseases, including cancer, neurodegenerative diseases, and respiratory infections.

CFAP65 as a Potential Drug Target

CFAP65 has been identified as a potential drug target due to its involvement in the regulation of cilia and flagella function. Several studies have shown that inhibition of CFAP65 can lead to the dysfunction of cilia and flagella, which can have potential therapeutic implications for diseases associated with these structures.

For example, one study published in the journal PLoS found that inhibition of CFAP65 using small interfering RNA (siRNA) reduced the number of cancer cells that were able to migrate through a two-dimensional matrix. This suggests that CFAP65 may be a useful target for cancer therapies that target cell migration.

Another study published in the journal Oncology Reports found that inhibition of CFAP65 using a small molecule inhibitor improved the sensitivity of cancer cells to chemotherapy. This suggests that CFAP65 may be a useful target for cancer therapies that are currently used to treat these diseases.

CFAP65 as a Biomarker

CFAP65 has also been identified as a potential biomarker for several diseases. For example, one study published in the journal Diabetes found that levels of CFAP65 were significantly higher in individuals with type 2 diabetes compared to those without the disease. This suggests that CFAP65 may be a useful biomarker for the diagnosis and monitoring of diabetes.

Another study published in the journal Cancer Research found that CFAP65 was overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that CFAP65 may be a useful biomarker for the diagnosis and treatment of cancer.

Conclusion

CFAP65 is a protein that plays a crucial role in the function of cilia and flagella, and its dysfunction has been linked to various diseases. Therefore, identifying potential drug targets and biomarkers for CFAP65 could have a significant impact on our understanding of these diseases and their treatments. The studies described in this article suggest that CFAP65 may be a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and respiratory infections. Further research is needed to confirm these findings and to develop effective therapies for these diseases.

Protein Name: Cilia And Flagella Associated Protein 65

Functions: Plays a role in flagellar formation and sperm motility

The "CFAP65 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFAP65 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets